Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

Biopharma industry zeal for obesity therapeutics does not appear to be dying down any time soon, with Eli Lilly and Co. entering a $1.3 billion deal with Nimbus Therapeutics LLC for a new small ...